Publications

  1. Pisansky TM, Pugh SL, Greenberg RE, Pervez N, Reed DR, Rosenthal SA, Mowat RB, Raben A, Buyyounouski MK, Kachnic LA, Bruner DW. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. JAMA. 2014 Apr 2; 311(13):1300-7.
    View PubMed
  2. Hallemeier CL, Choo R, Davis BJ, Leibovich BC, Costello BA, Pisansky TM. Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma--the Mayo Clinic experience. Urol Oncol. 2014 Jan; 32(1):24.e1-6. Epub 2013 Mar 11
    View PubMed
  3. Hallemeier CL, Davis BJ, Pisansky TM, Choo R. Late gastrointestinal morbidity in patients with stage I-II testicular seminoma treated with radiotherapy. Urol Oncol. 2013 Dec 11.
    View PubMed
  4. Hallemeier CL, Karnes RJ, Pisansky TM, Davis BJ, Gunderson LL, Leibovich BC, Haddock MG, Choo R. Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter. Am J Clin Oncol. 2013 Dec; 36(6):596-600.
    View PubMed
  5. Heckman MG, Tzou KS, Parker AS, Pisansky TM, Schild SE, Hilton TW, Patel VN, Pelaez L, Khor LY, Peterson JL, Daugherty LC, Vallow LA, Pollack A, Buskirk SJ. Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer. J Radiat Oncol. 2013 Sep 1; 2(3):309-14.
    View PubMed
  6. Peterson JL, Buskirk SJ, Heckman MG, Parker AS, Diehl NN, Tzou KS, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Pisansky TM. Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation Therapy for Prostate Cancer. ISRN Oncol. 2013; 2013:239241. Epub 2013 Mar 31.
    View PubMed
  7. Hallemeier CL, Pisansky TM, Davis BJ, Choo R. Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience. Urol Oncol. 2013 Nov; 31(8):1832-8. Epub 2012 Apr 25.
    View PubMed
  8. Heckman MG, Parker AS, Wu KJ, Hilton TW, Ko SJ, Pisansky TM, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer. Prostate. 2012 Dec 1; 72(16):1757-66. Epub 2012 Apr 18.
    View PubMed
  9. Kovalchuk N, Furutani KM, Macdonald OK, Pisansky TM. Dosimetric effect of interfractional needle displacement in prostate high-dose-rate brachytherapy. Brachytherapy. 2012 Mar-Apr; 11(2):111-8.
    View PubMed
  10. Hanisch LJ, Bryan CJ, James JL, Pisansky TM, Corbett TB, Parliament MB, Stewart CE, Hartford AC, Sandler H, Berk LB, Kachnic L, Bruner DW. Impact of sildenafil on marital and sexual adjustment in patients and their wives after radiotherapy and short-term androgen suppression for prostate cancer: analysis of RTOG 0215. Support Care Cancer. 2012 Nov; 20(11):2845-50. Epub 2012 Feb 22.
    View PubMed
  11. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1; 29(34):4491-7. Epub 2011 Oct 31.
    View PubMed
  12. Hallemeier CL, Choo R, Davis BJ, Pisansky TM, Gunderson LL, Leibovich BC, Haddock MG. Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Apr 1; 82(5):1938-43. Epub 2011 Apr 20.
    View PubMed
  13. Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky TM, Sandler H. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys. 2011 Sep 1; 81(1):1-7. Epub 2011 Apr 04.
    View PubMed
  14. Kachnic LA, Winter K, Wasserman T, Kelsen D, Ginsberg R, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Willett CG, Minsky BD. Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. Gastrointest Cancer Res. 2011 Mar; 4(2):45-52.
    View PubMed
  15. Watkins Bruner D, James JL, Bryan CJ, Pisansky TM, Rotman M, Corbett T, Speight J, Byhardt R, Sandler H, Bentzen S, Kachnic L, Berk L. Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med. 2011 Apr; 8(4):1228-38. Epub 2011 Jan 14.
    View PubMed
  16. Parker AS, Heckman MG, Sheinin Y, Wu KJ, Hilton TW, Diehl NN, Pisansky TM, Schild SE, Kwon ED, Buskirk SJ. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Apr 1; 79(5):1343-9. Epub 2010 Jul 02.
    View PubMed
  17. Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol. 2010 Jul; 96(1):6-12. Epub 2010 Apr 17.
    View PubMed
  18. Peterson JL, Buskirk SJ, Heckman MG, Crook JE, Ko SJ, Wehle MJ, Igel TC, Prussak KA, Pisansky TM. Late toxicity after postprostatectomy salvage radiation therapy. Radiother Oncol. 2009 Nov; 93(2):203-6. Epub 2009 Sep 18.
    View PubMed
  19. Parker AS, Heckman MG, Wu KJ, Crook JE, Hilton TW, Pisansky TM, Bernard JR, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Dec 1; 75(5):1364-70. Epub 2009 May 21.
    View PubMed
  20. Bernard JR Jr, Buskirk SJ, Heckman MG, Diehl NN, Ko SJ, Macdonald OK, Schild SE, Pisansky TM. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys. 2010 Mar 1; 76(3):735-40. Epub 2009 May 21.
    View PubMed
  21. Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Menard C. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Feb 1; 76(2):361-8. Epub 2009 Apr 23.
    View PubMed
  22. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009 Jun 1; 27(16):2638-44. Epub 2009 Apr 06.
    View PubMed
  23. Halyard M, Pisansky T, Dueck A, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez E. Radiotherapy and Adjuvant Trastuzumab in Stage I-IIA Breast Cancer: Tolerability and Adverse Event Data From the North Central Cancer Treatment Group Phase I Trial N9831. J Clin Oncol. 2009; 27:2638-44.
    View PubMed
  24. Pisansky TM, Gold DG, Furutani KM, Macdonald OK, McLaren RH, Mynderse LA, Wilson TM, Hebl JR, Choo R. High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. Mayo Clin Proc. 2008 Dec; 83(12):1364-72.
    View PubMed
  25. Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M 3rd, Pisansky TM, Seider M. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun 1; 74(2):377-82. Epub 2008 Oct 22.
    View PubMed
  26. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20; 25(15):2035-41.
    View PubMed
  27. Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, DeWeese TL, Sandler HM. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007 Aug 1; 68(5):1417-23. Epub 2007 Apr 06.
    View PubMed
  28. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007 Feb 1; 67(2):327-33.
    View PubMed
  29. Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05). Int J Radiat Oncol Biol Phys. 2007 Jan 1; 67(1):39-47.
    View PubMed
  30. Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology. 2006 Dec; 68(6):1257-62. Epub 2006 Dec 04.
    View PubMed
  31. Pisansky TM. External-beam radiotherapy for localized prostate cancer. N Engl J Med. 2006 Oct 12; 355(15):1583-91.
    View PubMed
  32. Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer. 2006 Oct 1; 107(7):1496-502.
    View PubMed
  33. Choo R, Kawakami J, Siemens R, Davis BJ, Brundage M, Pisansky TM. Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. BJU Int. 2006 Oct; 98(4):773-6.
    View PubMed
  34. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, Collie AC, Ferrigni RG, Myers RP, Prussak KA, Heckman MG, Crook JE, Parker AS, Igel TC. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol. 2006 Sep; 176(3):985-90.
    View PubMed
  35. Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):975-81. Epub 2006 Jun 05.
    View PubMed
  36. Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006 Aug 1; 65(5):1487-93. Epub 2006 Jun 05.
    View PubMed
  37. Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat. 2006 Jul; 98(2):217-22. Epub 2006 Mar 15.
    View PubMed
  38. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006 Mar 15; 64(4):1140-50. Epub 2005 Sep 29.
    View PubMed
  39. Gillin MT, Dunning BF, Lawton CA, Foley WD, Byhardt RW, Morton G, Baikadi M, Pisansky TT, Michalski JM, Ibbott G, Lopez F. Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. Brachytherapy. 2006; 5(3):152-6.
    View PubMed
  40. Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2005 Nov 1; 63(3):795-9.
    View PubMed
  41. Schallenkamp JM, Herman MG, Kruse JJ, Pisansky TM. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. International Journal of Radiation Oncology, Biology, Physics. 2005 Nov 1; 63(3):800-11.
    View PubMed
  42. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20; 353(16):1673-84.
    View PubMed
  43. Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4):956-64.
    View PubMed
  44. Pisansky TM. External beam radiotherapy as curative treatment of prostate cancer. Mayo Clin Proc. 2005 Jul; 80(7):883-98.
    View PubMed
  45. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol. 2005 Mar; 173(3):797-802.
    View PubMed
  46. Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: Can one size fit all? Int J Radiat Oncol Biol Phys. 2005 Feb 1; 61(2):409-14.
    View PubMed
  47. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005 Feb 1; 61(2):415-9.
    View PubMed
  48. Wittmer MH, Pisansky TM, Kruse JJ, Herman MG. Patient-specific daily pretreatment setup protocol using electronic portal imaging for radiation therapy. Journal of Applied Clinical Medical Physics. 2005; 6(4):1-13.
    View PubMed
  49. Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Herman MG, King BF, Geyer SM. Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2004 Nov 1; 60(3):767-76.
    View PubMed
  50. Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Hillman DW, Herman MG, King BF. Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression. Cancer J. 2004 Nov-Dec; 10(6):343-8.
    View PubMed
  51. Eshleman JS, Davis BJ, Pisansky TM, Wilson TM, Haddock MG, King BF, Darby CH, Lajoie WN, Oberg AL. Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: Extraprostatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys. 2004 Jun 1; 59(2):419-25.
    View PubMed
  52. Davis BJ, Brinkmann DH, Kruse JJ, Herman MG, LaJoie WN, Schwartz DJ, Pisansky TM, Kline RW. Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the prostate using an automated seed sorting algorithm. Brachytherapy. 2004; 3(2):106-12.
    View PubMed
  53. Pisansky TM. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer. Urology. 2003 Dec 29; 62(6B Suppl S):36-45.
    View PubMed
  54. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):915-28.
    View PubMed
  55. Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Comparison of alternative biochemical failure definitions' based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):929-43.
    View PubMed
  56. Herman MG, Pisansky TM, Kruse JJ, Prisciandaro JI, Davis BJ, King BF. Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):1131-40.
    View PubMed
  57. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 3; 349(1):17-26.
    View PubMed
  58. Davis BJ, Pisansky TM, Leibovich BC. Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. Curr Opin Urol. 2003 Mar; 13(2):117-22.
    View PubMed
  59. Schwartz DJ, Davis BJ, Vetter RJ, Pisansky TM, Herman MG, Wilson TM, LaJoie WN, Oberg AL. Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy. Brachytherapy. 2003; 2(2):98-102.
    View PubMed
  60. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002 Oct 15; 20(20):4141-9.
    View PubMed
  61. Kruse JJ, Herman MG, Hagness CR, Davis BJ, Garces YI, Haddock MG, Olivier KR, Stafford SL, Pisansky TM. Electronic and film portal images: A comparison of landmark visibility and review accuracy. Int J Radiat Oncol Biol Phys. 2002 Oct 1; 54(2):584-91.
    View PubMed
  62. Pisansky TM, Blute ML, Hillman DW, Davis BJ, Haddock MG, Suman VJ, Wilson TM, Zincke H. The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer. 2002 Aug 1; 95(3):513-9.
    View PubMed
  63. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1; 20(5):1167-74.
    View PubMed
  64. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE. Outcome of patients receiving radiation for cancer of the esophagus. Results of the 1992-1994 Patterns of Care Study. Classic Papers and Current Comments. 2002; 6:742-50.
  65. Minsky B, Pajak T, Ginsberg R, Pisansky T, Martenson J, Komaki R, Okawara G, Rosenthal S, Kelsen D Phase III Trial of Combined Modality Therapy for Esophageal Cancer: Standard Dose (50.4 Gy) vs. High Dose (64.8 Gy) Radiation Therapy J Clin Oncol. 2002.
    View PubMed
  66. Schild SE, Pisansky TM. The role of radiotherapy after radical prostatectomy. Urol Clin North Am. 2001 Aug; 28(3):629-37, x.
    View PubMed
  67. Buskirk SJ, Pisansky TM, Atkinson EJ, Schild SE, O'Brien PC, Wolfe JT, Zincke H. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy. Mayo Clin Proc. 2001 Jul; 76(7):702-6.
    View PubMed
  68. McCormick B, Strom E, Craighead PS, Kuske R, Hudis C, Ley J, Margolis L, Meyerwitz B, Morris E, Petrek J, Pierce L, Pisansky T, Rabinovitch R, Sneige N, Vicini F, Unger D, Winter K, Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Breast Cancer Working Group. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):56-7.
    View PubMed
  69. Sandler H, Shipley WU, Gomella L, Pienta K, Bard RH, Bruner D, Clark R, DeSilvio M, Gaspar L, Gillin M, Grignon D, Hammond E, Hanks G, Heydon KH, Kaufman DS, Lee WR, Michalski J, Mydlo J, Pisansky T, Pollack A, Porterfield H, Rifkin M, Roach M 3rd, Sanda Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):28-38.
    View PubMed
  70. Leibovich BC, Blute ML, Bostwick DG, Wilson TM, Pisansky TM, Davis BJ, Ramnani DM, Cheng L, Sebo TJ, Zincke H. Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology. 2000 Nov 1; 56(5):726-9.
    View PubMed
  71. Davis BJ, Pfeifer EA, Wilson TM, King BF, Eshleman JS, Pisansky TM. Prostate brachytherapy seed migration to the right ventricle found at autopsy following acute cardiac dysrhythmia. J Urol. 2000 Nov; 164(5):1661.
    View PubMed
  72. Davis BJ, Haddock MG, Wilson TM, Rothenberg HJ, Bostwick DG, Herman MG, Pisansky TM. Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: is extraprostatic seed placement necessary? Tech Urol. 2000 Jun; 6(2):70-7.
    View PubMed
  73. Pisansky TM, Davis BJ. Predictive factors in localized prostate cancer: implications for radiotherapy and clinical trial design. Semin Urol Oncol. 2000 May; 18(2):93-107.
    View PubMed
  74. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H, Bostwick DG. The cell cycle inhibitors p21(WAF1) and p27(KIP1) are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res. 2000 May; 6(5):1896-1899.
    View PubMed
  75. Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ, Zincke H. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. 2000 Apr; 163(4):1178-82.
    View PubMed
  76. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, Cheville JC, Ferrigni RG, Schild SE. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000 Mar; 163(3):845-50.
    View PubMed
  77. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol. 2000 Feb; 18(3):455-62.
    View PubMed
  78. Cheng L, Pisansky TM, Ramnani DM, Leibovich BC, Cheville JC, Slezak J, Bergstralh EJ, Zincke H, Bostwick DG. Extranodal extension in lymph node-positive prostate cancer. Mod Pathol. 2000 Feb; 13(2):113-8.
    View PubMed
  79. Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL, Scherer BG, Blute ML, Zincke H, Bostwick DG. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res. 1999 Oct; 5(10):2820-3.
    View PubMed
  80. Cheng L, Cheville JC, Pisansky TM, Sebo TJ, Slezak J, Bergstralh EJ, Neumann RM, Singh R, Pacelli A, Zincke H, Bostwick DG. Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol. 1999 Jul; 23(7):803-8.
    View PubMed
  81. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr, Pisansky TM. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol. 1999 Jul; 162(1):98-102.
    View PubMed
  82. Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, Sargent DJ, Bostwick DG. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer. 1999 Jun 15; 85(12):2630-7.
    View PubMed
  83. Coia LR, Minsky BD, John MJ, Haller DG, Landry J, Pisansky TM, Willett CG, Hoffman JP, Berkey BA, Owen JB, Hanks GE. The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus: results of the 1992-1994 Patterns of Care Study. Cancer. 1999 Jun 15; 85(12):2499-505.
    View PubMed
  84. Cheng L, Sebo TJ, Cheville JC, Pisansky TM, Slezak J, Bergstralh EJ, Pacelli A, Neumann RM, Zincke H, Bostwick DG. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer. 1999 Mar 15; 85(6):1293-9.
    View PubMed
  85. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, Salter M, Benson AB 3rd. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 1999 Feb 1; 43(3):517-23.
    View PubMed
  86. Cheng L, Sebo TJ, Slezak J, Pisansky TM, Bergstralh EJ, Neumann RM, Iczkowski KA, Zincke H, Bostwick DG. Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer. 1998 Nov 15; 83(10):2164-71.
    View PubMed
  87. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998 Jul; 16(7):2377-81.
    View PubMed
  88. Minsky BD, Coia L, Haller DG, Hoffman J, John M, Landry J, Pisansky TM, Willett C, Mahon I, Owen J, Berkey B, Katz A, Hanks G. Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey. J Clin Oncol. 1998 Jul; 16(7):2542-7.
    View PubMed
  89. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky T. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998 May 1; 82(9):1784-8.
    View PubMed
  90. Minsky BD, Coia L, Haller D, Hoffman J, John M, Landry J, Pisansky TM, Willett C, Mahon I, Owen J, Hanks G. Treatment systems guidelines for primary rectal cancer from the 1996 Patterns of Care Study. Int J Radiat Oncol Biol Phys. 1998 Apr 1; 41(1):21-7.
    View PubMed
  91. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998 Jan; 16(1):317-23.
    View PubMed
  92. Coia LR, Minsky BD, John MJ, Haller D, Landry J, Pisansky TM, Willet CG, Mahon I, Owen J, Hanks GE. Patterns of care study decision tree and management guidelines for esophageal cancer. American College of Radiology. Radiat Med. 1998; 16:321-7.
    View PubMed
  93. Srigley JR, Hutter RVP, Gelb AB, Henson DE, Kenney G, King BF, Raziuddin S, Pisansky TM. Current prognostic factors - renal cell carcinoma - workgroup no. 4. Cancer. 1997 Sep 1; 80(5):994-996.
    View PubMed
  94. Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer. 1997 Jun 1; 79(11):2154-61.
    View PubMed
  95. Schomberg PJ, Shanahan TG, Ingle JN, Donohue JH, Kuske RR, Sternfeld WC, Wold L, Cha SS, Petersen IA, Brindle JS, Halyard MY, Bollinger JW, Hawkins R, Pisansky TM. Accelerated hyperfractionation radiation therapy after lumpectomy and axillary lymph node dissection in patients with stage I or II breast cancer: pilot study. Radiology. 1997 Feb; 202(2):565-9.
    View PubMed
  96. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 1997 Jan 15; 79(2):337-44.
    View PubMed
  97. vander Kooy MJ, Pisansky TM, Cha SS, Blute ML. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology. 1997 Jan; 49(1):65-70.
    View PubMed
  98. Pisansky TM, Loprinzi CL, Cha SS, Fitzgibbons RJ, Grant CS, Hass AC, et al. Chemioterapia preoperatoria alternata nel trattamento del carcinoma mammario localmente avanzato: Risultati di uno studio pilota. Breast Cancer Digest. 1997:12-15.
  99. Coia LR, Minsky BD, John M, Pisansky TM, et al. 1996 decision trees and management guidelines. Semin Radiat Oncol. 1997; 7:163-81.
    View PubMed
  100. Schild SE, Pisansky TM, Kozelsky TF, Cha SS, Suman VJ, Burak SL, Ferrigni RG, Myers RP. Radiation therapy for elevated PSA levels after prostatectomy for prostate cancer. ASTRO School of Radiation Oncology: Prostate Cancer Symposium on Long Term Responses to Radiation, Atlanta, GA. 1997.
  101. Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys. 1996 Oct 1; 36(3):585-91.
    View PubMed
  102. Halyard MY, Grado GL, Schomberg PJ, Weaver AL, Grant CS, Pisansky TM. Conservative therapy of breast cancer. The Mayo Clinic experience. Am J Clin Oncol. 1996 Oct; 19(5):445-50.
    View PubMed
  103. Algaba F, Epstein JI, Aldape HC, Farrow GM, Lopezbeltran A, Maksem J, Orozco RE, Pacelli A, Pisansky TM, Trias I. Workgroup 5 - assessment of prostate carcinoma in core needle biopsy - definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer. 1996 Jul 15; 78(2):376-381.
    View PubMed
  104. Pisansky TM, Loprinzi CL, Cha SS, Fitzgibbons RJ Jr, Grant CS, Hass AC, Reuter NF, Wold LE, Ingle JN, Kardinal CG. A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma. Cancer. 1996 Jun 15; 77(12):2520-8.
    View PubMed
  105. Loprinzi CL, Okuno Sh, Pisansky TM, Sterioff S, Gaffey TA, Morton RF. Postsurgical changes of the breast that mimic inflammatory breast carcinoma. Mayo Clin Proc. 1996 Jun; 71(6):552-5.
    View PubMed
  106. Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pre-therapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys. 1996 Jan 1; 34(1):33-39.
    View PubMed
  107. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg R, Benson A 3rd. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. J Clin Oncol. 1996 Jan; 14(1):149-55.
    View PubMed
  108. Wold LE, Ingle JN, Pisansky TM, Johnson RE, Donohue JH. Prognostic factors for patients with carcinoma of the breast. Mayo Clin Proc. 1995 Jul; 70(7):678-9.
    View PubMed
  109. Minsky B, Neuberg D, Kelsen D, Pisansky TM, Ginsberg R, Benson III A. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus - a preliminary analysis of the phase II Intergroup trial 0122. Proc Am Soc Ther Radiol Oncol. 1995.
  110. Pisansky TM, Halyard MY, Weaver AL, Donohue JH, Grado GL, Grant CS, Hartmann LC, Ingle JN, Schomberg PJ, Wold LE. Breast conservation therapy for invasive breast cancer: a review of prior trials and the Mayo Clinic experience. Mayo Clin Proc. 1994 Jun; 69(6):515-24.
    View PubMed
  111. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, Oesterling JE. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1993 Nov; 11(11):2158-66.
    View PubMed
  112. Foo ML, McCullough EC, Foote RL, Pisansky TM, Shaw EG. Doses to radiation sensitive organs and structures located outside the radiotherapeutic target volume for four treatment situations. Int J Radiat Oncol Biol Phys. 1993 Sep 30; 27(2):403-17.
    View PubMed
  113. Pisansky TM, Ingle JN, Schaid DJ, Hass AC, Krook JE, Donohue JH, Witzig TE, Wold LE. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer. 1993 Aug 15; 72(4):1247-60.
    View PubMed
  114. Pisansky TM, Schaid DJ, Loprinzi CL, Donohue JH, Schray MF, Schomberg PJ. Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol. 1992 Oct; 15(5):376-87.
    View PubMed